KVYO insider files Form 144 after restricted stock vesting; $351.7K sale planned
Rhea-AI Filing Summary
Klaviyo, Inc. (KVYO) insider filed a Form 144 to sell 11,155 Class A shares through Fidelity Brokerage Services on the NYSE with an aggregate market value of $351,717.15. The shares were acquired on 08/15/2025 via restricted stock vesting and the planned approximate sale date is 08/18/2025. The filing shows total Class A shares outstanding of 116,897,730. No other sales in the past three months were reported in this notice. The filer represents they are not aware of undisclosed material adverse information.
Positive
- Insider sale is small relative to outstanding shares (11,155 vs 116,897,730), indicating limited market impact
- Securities were acquired through restricted stock vesting, signaling the sale is liquidity from compensation rather than external disposition
- Sale will be executed through a regulated broker (Fidelity) on the NYSE, consistent with standard disclosure practices
Negative
- Form does not list the filer's name or CIK in the provided text, limiting identification of the insider
- No indication of a 10b5-1 plan adoption date is provided, so the sale may not be pre-scheduled
Insights
TL;DR: Small-scale post-vesting sale by an insider; transaction size is immaterial relative to shares outstanding.
The filing documents a planned sale of 11,155 Class A shares valued at $351,717.15 following restricted stock vesting on 08/15/2025, to be executed through Fidelity on or about 08/18/2025. Against 116.9 million shares outstanding, this sale represents a de minimis fraction of equity, suggesting limited immediate dilution or signaling. The absence of any reported sales in the prior three months reduces concerns about a broader disposition pattern. This is a routine insider liquidity event tied to compensation rather than an external financing or material corporate action.
TL;DR: Governance-compliant disclosure of an insider sale tied to vesting; procedural safeguards appear followed.
The notice indicates the securities were acquired by restricted stock vesting and will be sold via a registered broker on the NYSE. The signer affirms no undisclosed material adverse information, and no 10b5-1 plan date is provided. Procedurally, the filing meets Rule 144 disclosure requirements by listing acquisition date, nature of acquisition, broker, and approximate sale date. For governance review, the transaction is routine and transparent, with no immediate red flags in the data supplied.